GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Minority Interest

Ludwig Enterprises (Ludwig Enterprises) Minority Interest : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Ludwig Enterprises's minority interest for the quarter that ended in Mar. 2024 was $0.00 Mil.


Ludwig Enterprises Minority Interest Historical Data

The historical data trend for Ludwig Enterprises's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Minority Interest Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
Minority Interest
- -

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Minority Interest Get a 7-Day Free Trial - - - - -

Ludwig Enterprises Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.